Association between Beta-Sympathomimetic Tocolysis and Risk of Autistic Spectrum Disorders, Behavioural and Developmental Outcome in Toddlers

Authors

  • Mengühan Araz Altay Department of Child and Adolescent Psychiatry, Edirne Sultan 1. Murat State Hospital, Edirne
  • Işık Görker Department of Child and Adolescent Psychiatry, Trakya University Faculty of Medicine, Edirne
  • Rakhshanda Aslanova Department of Obstetrics and Gynecology, Trakya University Faculty of Medicine, Edirne
  • Leyla Bozatlı Department of Child and Adolescent Psychiatry, Trakya University Faculty of Medicine, Edirne
  • Nesrin Turan Department of Biostatistics and Medical Informatics, Trakya University Faculty of Medicine, Edirne
  • Petek Balkanlı Kaplan Department of Obstetrics and Gynecology, Trakya University Faculty of Medicine, Edirne

DOI:

https://doi.org/10.3889/oamjms.2017.153

Keywords:

Tocolysis, Beta-mimetics, Autism spectrum disorder, Behavioural and Developmental disorders

Abstract

AIM: To investigate whether maternal intravenous beta-mimetic tocolytic therapy increases the risk of autistic spectrum disorders (ASD) and poorer behavioural and developmental outcomes.

METHOD: Our study is a prospective case-control study among 90 children between 1.5 and three years old. Cases (n = 46) were toddlers with betamimetic tocolytic exposure; control group toddlers (n = 44) were tocolytic untreated. Treated and untreated groups were also divided into subgroups: term and preterm delivered. The gestational age of tocolytic treatment start, the dose and duration of exposure in hours were obtained from obstetric medical records. The Brief Infant-Toddler Social and Emotional Assessment (BITSEA), the Modified Checklist for Autism in Toddlers (M-CHAT) and the Denver Developmental Screening Test (DDST) tests were applied for evaluation of social, emotional problems, autism and developmental disorders.

RESULTS: Term and preterm born toddlers treated tocolytically in utero didn’t demonstrate a higher risk of autistic disorders or poorer behavioural and developmental results than controls. In the preterm group, the earliest start of tocolytic treatment was correlated with toddlers lower score of the Competencies Scale (p = 0.009) and a higher score of the Problems Scale (p = 0.048). Also, we concluded that preterm membrane rupture was associated with higher ASD risk in the untreated group (p = 0.043).

CONCLUSION: Exposure to betamimetics during pregnancy was not associated with an increased risk of autism, behavioural and developmental disorders.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Lumley J. The epidemiology of preterm birth. Bailliere's clinical obstetrics and gynaecology. 1993;7(3):477-98. https://doi.org/10.1016/S0950-3552(05)80445-6

Hack M, Fanaroff AA. Outcomes of children of extremely low birthweight and gestational age in the 1990's. Early human development. 1999;53(3):193-218. https://doi.org/10.1016/S0378-3782(98)00052-8

Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A. Tocolytics for preterm labour: a systematic review. Obstetrics and gynaecology. 1999;94(5 Pt 2):869-77. https://doi.org/10.1097/00006250-199911001-00043

King JF, Grant A, Keirse MJ, Chalmers I. Beta-mimetics in preterm labour: an overview of the randomized controlled trials. British journal of obstetrics and gynaecology. 1988;95(3):211-22. https://doi.org/10.1111/j.1471-0528.1988.tb06860.x PMid:2897207

Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. The Cochrane database of systematic reviews. 2006(3):Cd004454. https://doi.org/10.1002/14651858.CD004454.pub2

Haas DM, Imperiale TF, Kirkpatrick PR, Klein RW, Zollinger TW, Golichowski AM. Tocolytic therapy: a meta-analysis and decision analysis. Obstetrics and gynecology. 2009;113(3):585-94. https://doi.org/10.1097/AOG.0b013e318199924a PMid:19300321

Hill WC. Risks and complications of tocolysis. Clinical obstetrics and gynecology. 1995;38(4):725-45. https://doi.org/10.1097/00003081-199538040-00008 PMid:8616971

Garofolo MC, Seidler FJ, Cousins MM, Tate CA, Qiao D, Slotkin TA. Developmental toxicity of terbutaline: critical periods for sex-selective effects on macromolecules and DNA synthesis in rat brain, heart, and liver. Brain research bulletin. 2003;59(4):319-29. https://doi.org/10.1016/S0361-9230(02)00925-5

Rhodes MC, Seidler FJ, Abdel-Rahman A, Tate CA, Nyska A, Rincavage HL, et al. Terbutaline is a developmental neurotoxicant: effects on neuroproteins and morphology in cerebellum, hippocampus, and somatosensory cortex. The Journal of pharmacology and experimental therapeutics. 2004;308(2):529-37. https://doi.org/10.1124/jpet.103.060095 PMid:14610225

Slotkin TA, Baker FE, Dobbins SS, Eylers JP, Lappi SE, Seidler FJ. Prenatal terbutaline exposure in the rat: selective effects on development of noradrenergic projections to cerebellum. Brain research bulletin. 1989;23(4-5):263-5. https://doi.org/10.1016/0361-9230(89)90206-2

Slotkin TA, Kudlacz EM, Lappi SE, Tayyeb MI, Seidler FJ. Fetal terbutaline exposure causes selective postnatal increases in cerebellar alpha-adrenergic receptor binding. Life sciences. 1990;47(22):2051-7. https://doi.org/10.1016/0024-3205(90)90440-3

Weiss ER, Maness P, Lauder JM. Why do neurotransmitters act like growth factors? Perspectives on developmental neurobiology. 1998;5(4):323-35. PMid:10533523

Stein HM, Oyama K, Sapien R, Chappell BA, Padbury JF. Prolonged betaagonist infusion does not induce desensitization or down-regulation of betaadrenergic receptors in newborn sheep. Pediatric research. 1992;31(5):462-7. https://doi.org/10.1203/00006450-199205000-00009 PMid:1351281

Pitzer M, Schmidt MH, Esser G, Laucht M. Child development after maternal tocolysis with beta-sympathomimetic drugs. Child psychiatry and human development. 2001;31(3):165-82. https://doi.org/10.1023/A:1026419720410 PMid:11196009

Slotkin TA, Auman JT, Seidler FJ. Ontogenesis of beta-adrenoceptor signaling: implications for perinatal physiology and for fetal effects of tocolytic drugs. The Journal of pharmacology and experimental therapeutics. 2003;306(1):1-7. https://doi.org/10.1124/jpet.102.048421 PMid:12682213

Martineau J, Herault J, Petit E, Guerin P, Hameury L, Perrot A, et al. Catecholaminergic metabolism and autism. Developmental medicine and child neurology. 1994;36(8):688-97. https://doi.org/10.1111/j.1469-8749.1994.tb11911.x PMid:7914177

Kemper TL, Bauman M. Neuropathology of infantile autism. Journal of neuropathology and experimental neurology. 1998;57(7):645-52. https://doi.org/10.1097/00005072-199807000-00001

Slotkin TA, Tate CA, Cousins MM, Seidler FJ. Imbalances emerge in cardiac autonomic cell signaling after neonatal exposure to terbutaline or chlorpyrifos, alone or in combination. Brain research Developmental brain research. 2005;160(2):219-30. https://doi.org/10.1016/j.devbrainres.2005.09.006 PMid:16256208

Ming X, Julu PO, Brimacombe M, Connor S, Daniels ML. Reduced cardiac parasympathetic activity in children with autism. Brain & development. 2005;27(7):509-16. https://doi.org/10.1016/j.braindev.2005.01.003 PMid:16198209

Witter FR, Zimmerman AW, Reichmann JP, Connors SL. In utero beta 2 adrenergic agonist exposure and adverse neurophysiologic and behavioural outcomes. American journal of obstetrics and gynecology. 2009;201(6):553-9. https://doi.org/10.1016/j.ajog.2009.07.010 PMid:19961985

Karabekiroglu K, Rodopman-Arman A, Ay P, Ozkesen M, Akbas S, Tasdemir GN, et al. The reliability and validity of the Turkish version of the brief infant-toddler social emotional assessment (BITSEA). Infant behavior & development. 2009;32(3):291-7. https://doi.org/10.1016/j.infbeh.2009.03.003 PMid:19411111

Carter AS, Briggs-Gowan MJ. Infant-Todler Sosial and Emotional Assesment (ITSEA) and Brief Infant-Todler Social and Emotional Assesment (BITSEA), 2006.

Briggs-Gowan MJ, Carter AS, Irwin JR, Wachtel K, Cicchetti DV. The Brief Infant-Toddler Social and Emotional Assessment: screening for social-emotional problems and delays in competence. Journal of pediatric psychology. 2004;29(2):143-55. https://doi.org/10.1093/jpepsy/jsh017 PMid:15096535

Spittle AJ, Anderson PJ, Lee KJ, Ferretti C, Eeles A, Orton J, et al. Preventive care at home for very preterm infants improves infant and caregiver outcomes at 2 years. Pediatrics. 2010;126(1):e171-e8. https://doi.org/10.1542/peds.2009-3137 PMid:20547650

Kara B, Mukaddes NM, Altinkaya I, Guntepe D, Gokcay G, Ozmen M. Using the Modified Checklist for Autism in Toddlers in a well-child clinic in Turkey: adapting the screening method based on culture and setting. Autism : the international journal of research and practice. 2014;18(3):331-8. https://doi.org/10.1177/1362361312467864 PMid:23175752

Robins DL, Fein D, Barton ML, Green JA. The Modified Checklist for Autism in Toddlers: an initial study investigating the early detection of autism and pervasive developmental disorders. Journal of autism and developmental disorders. 2001;31(2):131-44. https://doi.org/10.1023/A:1010738829569 PMid:11450812

Shahshahani S, Sajedi F, Azari N, Vameghi R, Kazemnejad A, Tonekaboni SH. Evaluating the Validity and Reliability of PDQ-II and Comparison with DDST-II for Two Step Developmental Screening. Iranian journal of pediatrics. 2011;21(3):343-9. PMid:23056811 PMCid:PMC3446190

Croen LA, Connors SL, Matevia M, Qian Y, Newschaffer C, Zimmerman AW. Prenatal exposure to beta2-adrenergic receptor agonists and risk of autism spectrum disorders. Journal of neurodevelopmental disorders. 2011;3(4):307-15. https://doi.org/10.1007/s11689-011-9093-4 PMid:21874331 PMCid:PMC3261266

Gidaya NB, Lee BK, Burstyn I, Michael Y, Newschaffer CJ, Mortensen EL. Pediatrics. In utero Exposure to β-2-Adrenergic Receptor Agonist Drugs and Risk for Autism Spectrum Disorders. 2016;137(2):e20151316.

Atladóttir HÓ , Schendel DE , Henriksen TB, Hjort L, Parner ET. Gestational Age and Autism Spectrum Disorder: Trends in Risk Over Time. Autism Res. 2016;9(2):224-31. https://doi.org/10.1002/aur.1525 PMid:26363410

MacKay DF, Smith GC, Dobbie R, Pell JP. Gestational age at delivery and special educational need: retrospective cohort study of 407,503 schoolchildren. PLoS medicine. 2010;7(6):e1000289. https://doi.org/10.1371/journal.pmed.1000289 PMid:20543995 PMCid:PMC2882432

Connors SL, Crowell DE, Eberhart CG, Copeland J, Newschaffer CJ, Spence SJ, et al. beta2-adrenergic receptor activation and genetic polymorphisms in autism: data from dizygotic twins. Journal of child neurology. 2005;20(11):876-84. https://doi.org/10.1177/08830738050200110401 PMid:16417856

Polowczyk D, Tejani N, Lauersen N, Siddiq F. Evaluation of seven- to nine year-old children exposed to ritodrine in utero. Obstetrics and gynecology. 1984;64(4):485-8. PMid:6483295

Hadders-Algra M, Touwen BC, Huisjes HJ. Long-term follow-up of children prenatally exposed to ritodrine. British journal of obstetrics and gynaecology. 1986;93(2):156-61. https://doi.org/10.1111/j.1471-0528.1986.tb07880.x PMid:3947590

Moore T, Johnson S, Hennessy E, Marlow N. Screening for autism in extremely preterm infants: problems in interpretation. Developmental Medicine & Child Neurology. 2012;54(6):514-20. https://doi.org/10.1111/j.1469-8749.2012.04265.x PMid:22458327

Joseph RM, O'Shea TM, Allred EN, Heeren T, Hirtz D, Paneth N et al Prevalence and associated features of autism spectrum disorder in extremely low gestational age newborns at age 10 years. Autism Res. 2017;10(2):224-232. https://doi.org/10.1002/aur.1644 PMid:27220677

Dudova I, Kasparova M, Markova D, Zemankova J, Beranova S, Urbanek T et al. Screening for autism in preterm children with extremely low and very low birth weight. Neuropsychiatr Dis Treat. 2014;10:277-82. https://doi.org/10.2147/NDT.S57057 PMid:24627633 PMCid:PMC3931701

Tran PL, Lehti V, Lampi KM, et al. Smoking during pregnancy and risk of autism spectrum disorder in a Finnish National Birth Cohort. Paediatr Perinat Epidemiol. 2013;27:266-74. https://doi.org/10.1111/ppe.12043 PMid:23574415 PMCid:PMC3652271

Jiang H, Liu L, Sun DL, Yin XN, Chen ZD, Wu CA et al. Interaction between passive smoking and folic acid supplement during pregnancy on autism spectrum disorder behaviors in children aged 3 years. Zhonghua Liu Xing Bing Xue Za Zhi. 2016;37(7):940-4. PMid:27453101

Kalkbrenner AE, Braun JM, Durkin MS, Maenner MJ, Cunniff C, Lee L-C, et al. Maternal smoking during pregnancy and the prevalence of autism spectrum disorders, using data from the Autism and Developmental Disabilities Monitoring Network. Environmental health perspectives. 2012;120(7):1042. https://doi.org/10.1289/ehp.1104556 PMid:22534110 PMCid:PMC3404663

Tang S, Wang Y, Gong X, Wang G .A Meta-Analysis of Maternal Smoking during Pregnancy and Autism Spectrum Disorder Risk in Offspring. Int J Environ Res Public Health. 2015;12(9):10418-31. https://doi.org/10.3390/ijerph120910418 PMid:26343689 PMCid:PMC4586619

Lee BK, Gardner RM, Dal H, Svensson A, Galanti MR, Rai D, et al. Brief report: maternal smoking during pregnancy and autism spectrum disorders. Journal of autism and developmental disorders. 2012;42(9):2000-5. https://doi.org/10.1007/s10803-011-1425-4 PMid:22173844

ACOG practice bulletin. Management of preterm labor. Number 43, May 2003. International journal of gynaecology and obstetrics. 2003;82(1):127-35. https://doi.org/10.1016/S0020-7292(03)00247-9

Published

2017-09-10

How to Cite

1.
Altay MA, Görker I, Aslanova R, Bozatlı L, Turan N, Kaplan PB. Association between Beta-Sympathomimetic Tocolysis and Risk of Autistic Spectrum Disorders, Behavioural and Developmental Outcome in Toddlers. Open Access Maced J Med Sci [Internet]. 2017 Sep. 10 [cited 2024 Mar. 5];5(6):730-5. Available from: https://oamjms.eu/index.php/mjms/article/view/oamjms.2017.153

Issue

Section

B - Clinical Sciences